A Phase 3 interventional study of SABR boost and de-escalated chemoradiation and Standard chemoradiation in Head and Neck Cancer, Oropharynx Cancer and Human Papilloma Virus, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Oropharyngeal Neoplasms with a site in Canada — 9 open to participants now, 14 under way, 5 of them phase 3. Oropharyngeal Neoplasms · Canada.
Among the 25 studies in Oropharyngeal Neoplasms with a site in Canada, this one is the 4th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2020, is one of 4 in phase 3, reaches primary completion later than 12 of the 13 other live ones, and was the 12th registered.
370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.
Browse Oropharyngeal Neoplasms studies →9 of the 25 studies in Oropharyngeal Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
Corbus Pharmaceuticals Inc. · Sites in Canada, United States, Austria and 11 more countries
Ages 18+
Canadian Cancer Trials Group · Sites in Canada, United States
Ages 18+
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18–65
National Cancer Institute (NCI) · Sites in Canada, United States
Ages 18+
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada, Australia
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 8 · Phase 4 1
First in 1999; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 360 is above the median of 52 across 265 interventional studies indexed under Oropharyngeal Neoplasms.
Median enrollment 76 across the 20 interventional studies, 65 across the 3 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 25 have an industry lead sponsor. The 10 most frequent:
Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.
Centre hospitalier de l'Université de Montréal (CHUM) has 3 studies filed under Oropharyngeal Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies in Oropharyngeal Neoplasms with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04901234Centre hospitalier de l'Université de Montréal (CHUM)Adaptive RadioTherapy for OroPharynx Cancer | 2026-12 |
| NCT06578871London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sSurgery and Reducing Ionizing Radiation of the Unknown Primary | 2026-12-31 |
| NCT06965738University Health Network, TorontoBuccal Fat for Transoral Robotic Lateral Oropharyngectomy Defects to and Postoperative Pain | 2027-04-01 |
| NCT05172245National Cancer Institute (NCI)Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | 2027-07-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies in Oropharyngeal Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized clinical trial comparing the outcomes of short-course chemoradiation consisting in stereotactic boost to the gross tumor and de-esclalated chemoradiation to the elective neck in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation.
Concurrent platinum-based chemoradiation remains the standard of care in locally advanced head and neck cancer. The current standard radiation regimen consists in a 7-week course of conventionally fractionated radiotherapy to the gross tumor volume (GTV), along with bilateral prophylactic neck irradiation to an elective dose of \~ 50 Gy in 2 Gy per fraction. In addition to being cumbersome, the current protracted daily radiation course is associated with high rates of acute and late toxicities and significant deterioration of patients' quality of life. In the light of the remarkably improved prognosis of the distinct subgroup of HPV-OPC, there is growing interest for treatment de-intensification strategies in contemporaneous OPC cohorts.
Stereotactic ablative radiotherapy (SABR) allows for ultra-precise delivery of ablative radiation dose over a small number of fractions, by combining sharp dose gradients with use of optimal image guidance. The increased conformity and reduced margins used in SABR can substantially reduce the dose to surrounding organs at risk and could therefore reduce toxicity. In addition, previous work has shown that an elective dose of 40 Gy in 2 Gy per fraction, in conjunction with chemotherapy, is sufficient for microscopic sterilisation of cancer cells and can translate into a reduction of toxicities.
The goal of this trial is to compare the efficacy and safety of short-course chemoradiation consisting in stereotactic boost to the gross tumor of 14 Gy in 2 fractions followed by de-esclalated chemoradiation (40 Gy in 20 fractions and concurrent 2 cycles of Cisplatin 100mg/m2) in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation (70 Gy in 33 fractions with 2-3 cycles of Cisplatin 100mg/m2).
This is an open label randomized phase III non inferiority trial. Patients will be randomized using a 1:1 ratio between the standard and the experimental arm and will be stratified by tumor stage and use of concurrent chemotherapy.
370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.
This study's planned enrollment of 360 is above the median of 52 across 265 interventional studies indexed under Oropharyngeal Neoplasms.
Browse Oropharyngeal Neoplasms studies →Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.
Compared within Oropharyngeal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SABR boost of 14 Gy in 2 fractions to the GTV, immediately followed by de-escalated chemoradiation. De-escalated chemoradiation will consist in 40 Gy in 20 fractions with concurrent high dose Cisplatin (3-weekly, 100 mg/m2) for 2 cycles, aiming for a cumulative dose of 200 mg/m2.
Radiation: SABR boost and de-escalated chemoradiation
The standard arm will consist of conventionally radiation to a dose of 70 Gy in 33 fractions concurrently with high dose Cisplatin (3-weekly, 100 mg/m2) for 2-3 cycles, aiming for a cumulative dose of ≥ 200 mg/m2.
Radiation: Standard chemoradiation
Stereotactic body radiotherapy boost to the gross tumor volume to a dose of 14 Gy in 2 fractions, followed by cisplatin-based chemoradiation to a dose of 40 Gy in 20 fractions
Standard Cisplatin-based chemoradiation to a dose of 70 Gy in 33 fractions
Progression free survival
Patient alive with no local, regional or distant recurrence at 2 years after the end of chemoradiation
Time frame: 2 years after the end of chemoradiation
Subacute toxicity
Rate of grade ≥ 3 subacute toxicity
Time frame: Between 2 and 6 months after the end of chemoradiation
Acute toxicity
Rate of grade ≥ 3 acute toxicity
Time frame: Less than 2 months after the end of chemoradiation
Late toxicity
Rate of grade ≥ 3 late toxicity
Time frame: Between 6 months and 5-years after the end of chemoradiation
OS
Overall survival
Time frame: At 2- and 5-years after the end of chemoradiation
locoregional control
Patient alive with locoregional control
Time frame: At 2- and 5-years after the end of chemoradiation
Head and neck symptom burden
Patient-reported head and neck symptom burden as measured by the MD Anderson Symptom Inventory Head and Neck Cancer Module. The core and head and neck cancer specific symptoms are rated on a 0-10 scale to indicate the presence and severity of the symptoms. Lower scores represent better functioning and quality of life.
Time frame: At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation
Dysphagia
Patient-reported dysphagia as measured by the MD Anderson Dysphagia Index. Overall score ranges from 0 to 100, with higher score representing better functioning and quality of life.
Time frame: At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation
Time from treatment start to return to work
Time from first day of treatment start to first day of return to work.
Time frame: Measured in days and reported at 2-years post-treatment
Plan to share: No
Started Feb 2020 (actual). Primary completion is estimated for Dec 2028, 106 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre hospitalier de l'Université de Montréal (CHUM) →